NetworkNewsBreaks – Scinai Immunotherapeutics Lt
Post# of 88
(Total Views: 130)
Posted On: 03/12/2024 4:44:16 PM
NetworkNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Showcasing Services, Meeting with Investors at Upcoming BIO-Europe Spring 2024
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing CDMO services through its Scinai Bioservices business unit, will be participating at this month’s BIO-Europe Spring 2024 conference. The conference is scheduled for March 18–20, 2024, in Barcelona. According to the announcement, Scinai management will be attending the event and will be available for discussions with prospective clients, potential pharma partners that may be interested in co-advancing or in-licensing Scinai’s innovative NanoAb for the treatment of mild to moderate plaque psoriasis, and institutional and private investors. In addition, the company is hosting a booth in the conference exhibition space showcasing the company’s cGMP biologics CDMO and innovative NanoAb pipeline.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://nnw.fm/SCNI
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing CDMO services through its Scinai Bioservices business unit, will be participating at this month’s BIO-Europe Spring 2024 conference. The conference is scheduled for March 18–20, 2024, in Barcelona. According to the announcement, Scinai management will be attending the event and will be available for discussions with prospective clients, potential pharma partners that may be interested in co-advancing or in-licensing Scinai’s innovative NanoAb for the treatment of mild to moderate plaque psoriasis, and institutional and private investors. In addition, the company is hosting a booth in the conference exhibition space showcasing the company’s cGMP biologics CDMO and innovative NanoAb pipeline.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://nnw.fm/SCNI
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)